Literature DB >> 21543643

Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli.

Dagmar Von Bubnoff1, Marina Scheler, Helene Wilms, Rolf Fimmers, Thomas Bieber.   

Abstract

Dendritic cells (DCs) can induce tolerance or immunity. We identified and characterized an IDO-expressing and an IDO-negative human DC population after stimulation by various proinflammatory stimuli. IDO expression was strongly dependent on the maturation status of the cells (CD83-positive cells only). The two DC subpopulations remained IDO positive and IDO negative, respectively, over a time period of at least 48 h. IDO enzyme activity of human DCs was highest during stimulation by strongly maturation-inducing TLR ligands such as highly purified LPS (TLR4 ligand) or polyriboinosinic-polyribocytidilic acid (TLR3 ligand); factors of the adaptive immune system such as IFN-γ, a mixture of cytokines, and IFN-α had lesser stimulatory capacity for IDO induction and activity. After stimulation with CD40L, IDO-positive DCs expressed significantly increased levels of B7 family molecules such as CD40, CD80, CD86, ICOS ligand, as well as PD-L1 (B7-H1) and PD-L2 (B7-DC) compared with the IDO-negative DC subset. At the same time, the inhibitory receptors Ig-like transcripts 3 and 4 were significantly downregulated on IDO-positive cells. Functionally, IDO-positive DCs produced significantly more IL-1β and IL-15 and less IL-10 and IL-6 than the IDO-negative subset after CD40L stimulation. These results show that IDO expression is associated with a distinctive phenotype and functional capacity in mature DCs. It seems likely that the IDO-positive DC subset possesses a regulatory function and might skew a T cell response toward tolerance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543643     DOI: 10.4049/jimmunol.1003151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.

Authors:  Barbara Dillinger; Sarah Ahmadi-Erber; Manuel Lau; Markus A Hoelzl; Friedrich Erhart; Birgit Juergens; Dietmar Fuchs; Andreas Heitger; Stephan Ladisch; Alexander M Dohnal
Journal:  Cell Immunol       Date:  2018-02-02       Impact factor: 4.868

2.  Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Authors:  M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

3.  The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Authors:  Sara Trabanelli; Darina Očadlíková; Marilena Ciciarello; Valentina Salvestrini; Mariangela Lecciso; Camilla Jandus; Richard Metz; Cecilia Evangelisti; Lisa Laury-Kleintop; Pedro Romero; George C Prendergast; Antonio Curti; Roberto M Lemoli
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

4.  Local Expression of Indoleamine 2,3, Dioxygenase Prolongs Allogenic Skin Graft Take in a Mouse Model.

Authors:  Mohammadreza Pakyari; Ali Farokhi; Reza B Jalili; Ruhangiz T Kilani; Erin Brown; Aziz Ghahary
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-02-13       Impact factor: 4.730

5.  Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.

Authors:  Hiroyasu Ito; Tatsuya Ando; Yuko Arioka; Kuniaki Saito; Mitsuru Seishima
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

6.  Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients.

Authors:  S Schulz; A Landi; R Garg; J A Wilson; S van Drunen Littel-van den Hurk
Journal:  Clin Exp Immunol       Date:  2015-06       Impact factor: 4.330

7.  The cystine/glutamate antiporter regulates indoleamine 2,3-dioxygenase protein levels and enzymatic activity in human dendritic cells.

Authors:  Mildred L Mattox; June A D'Angelo; Zachary M Grimes; Edda Fiebiger; Bonny L Dickinson
Journal:  Am J Clin Exp Immunol       Date:  2012-11-30

8.  Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Authors:  Arta M Monjazeb; Michael S Kent; Steven K Grossenbacher; Christine Mall; Anthony E Zamora; Annie Mirsoian; Mingyi Chen; Amir Kol; Stephen L Shiao; Abhinav Reddy; Julian R Perks; William T N Culp; Ellen E Sparger; Robert J Canter; Gail D Sckisel; William J Murphy
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

9.  The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment.

Authors:  Fangxuan Li; Jinchao Huang; Shixia Li; Hui Li; Jinpu Yu; Xiubao Ren; Juntian Liu
Journal:  Tumour Biol       Date:  2014-05-29

10.  Exaggerated IDO1 expression and activity in Langerhans cells from patients with atopic dermatitis upon viral stimulation: a potential predictive biomarker for high risk of Eczema herpeticum.

Authors:  A Staudacher; T Hinz; N Novak; D von Bubnoff; T Bieber
Journal:  Allergy       Date:  2015-09-02       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.